SLC5A2 and chronic kidney disease: Although SGLT2 inhibitors have emerged as glucose‐lowering agents through their ability to induce glycosuria, several large trials, including DAPA‐CKD (Heerspink et al., 2020) and EMPA‐KIDNEY (The EMPA‐KIDNEY Collaborative Group et al., 2023), have shown that SGLT2 inhibitors also slow the progression of CKD in patients with and without diabetes mellitus.